Dodge & Cox Has $3.25 Billion Position in Sanofi $SNY

Key Points

• Dodge & Cox trimmed its Sanofi stake by 3.9% in Q3 to 68,931,747 shares (2.81% of Sanofi), a position worth about $3.25 billion and ranking as its 21st-largest holding.
• Other institutions also shifted positions—examples include Brighton Jones (+52.6%) and AQR (+107.2%)—though total institutional and hedge-fund ownership is only about 14.03% of the company.
• Analysts are mixed: five Buy vs nine Hold with an average consensus of Hold and a $62.67 target, while Sanofi trades near $43.60 (12‑month range $43.34–$59.17) with a market cap around $106.3B and a P/E of 12.11.

Dodge & Cox cut its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 3.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,931,747 shares of the company's stock after selling 2,786,568 shares during the period. Sanofi comprises approximately 1.8% of Dodge & Cox's portfolio, making the stock its 21st largest position. Dodge & Cox owned 2.81% of Sanofi worth $3,253,578,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock worth $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company's stock valued at $326,000 after purchasing an additional 347 shares during the period. Finally, Savant Capital LLC raised its position in Sanofi by 17.1% during the 2nd quarter. Savant Capital LLC now owns 8,423 shares of the company's stock worth $407,000 after purchasing an additional 1,227 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Sanofi in a report on Monday, December 8th. UBS Group restated a "neutral" rating on shares of Sanofi in a research report on Friday, January 16th. HSBC reiterated a "buy" rating on shares of Sanofi in a report on Wednesday, December 10th. TD Cowen reissued a "hold" rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Bank of America lowered shares of Sanofi from a "buy" rating to a "neutral" rating in a report on Thursday, February 12th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $43.60 on Friday. Sanofi has a twelve month low of $43.34 and a twelve month high of $59.17. The stock's 50 day moving average is $46.85 and its 200-day moving average is $48.24. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $106.34 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.13 and a beta of 0.45.

Sanofi Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.